Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Lufotrelvir (PF-07304814) in Hospitalized COVID-19 Patients
NCT04535167Phase 1Completed
- Sponsor
- Pfizer
- Start
- Sep 2020
- Primary completion
- Jun 2021
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 4
01
Overview
Phase 1, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing Lufotrelvir with Placebo (2 arms). Primary endpoints: Number of Participants With TEAEs, SAEs, and Severe TEAEs, Number of Participants With Discontinuations From Study/Study Drug or Dose Reduction Due to TEAEs and 4 more. Started Sep 2020; status: completed.
02
Drugs
lufotrelvir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04535167.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04535167.